Skip to content
Research Article Open access CC BY 4.0

Real World Experience of the First Cardio-Oncology Unit Implantation in Morocco

Rachida Habbal, Anas Maaroufi, Safia Ouarrak, Rime Benmalek, Hajar Bendahou, Soukaina Zahri, Khawla Chawki, Yasmina Berrada, Safia Zafad, Ghali Benjelloune, Meryem Charkaoui, Nezha Taoufiq

Cardiology and Angiology: An International Journal · pp. 50–61 · Published 20 Apr 2024

10.9734/ca/2024/v13i2406

Abstract

Cardiotoxicity presents a multifaceted challenge with significant implications. Our investigation delving into cardiotoxicity linked with Anthracyclines and Trastuzumab has shed light on these agents as frequent culprits, revealing a spectrum of cardiac complications like heart failure, arrhythmias, hypertension, QTc prolongation, and arterial and venous thromboses. However, the true prevalence of cardiotoxicity is often underestimated due to delayed effects, patient attrition post-remission, and the emergence of novel therapeutic agents. The collaboration between cardiology and oncology is expanding, encompassing Cardio-Hematology and its impact on conditions like multiple myeloma, leukemia, and lymphomas. This evolving convergence underscores the necessity for interdisciplinary collaboration. The study findings highlight the significance of adhering to guidelines while acknowledging that guidelines should serve as aids rather than substitutes for clinical judgment within multidisciplinary tumor boards (MTBs). Enhanced by ongoing research, these guidelines serve as instruments empowering clinicians to make well-informed decisions tailored to individual patient needs. Scientific research remains pivotal, guiding progress and offering promise for enhanced outcomes in the global battle against cancer.

Cardiotoxicity chemotherapy heart failure cardio-oncology Morocco

References (24)

  1. 1 Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer [DOI]
  2. 2 Identification of the molecular basis of doxorubicin-induced cardiotoxicity [DOI]
  3. 3 Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies [DOI]
  4. 4 Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline [DOI]
  5. 5 Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study [DOI]
  6. 6 Causes of death among cancer patients [DOI]
  7. 7 Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. [DOI]
  8. 8 Cardiovascular Toxic Effects of Targeted Cancer Therapies [DOI]
  9. 9 Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group [DOI]
  10. 10 Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study [DOI]
  11. 11 A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity [DOI]
  12. 12 Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas [DOI]
  13. 13 Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis [DOI]
  14. 14 Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis [DOI]
  15. 15 Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients With Breast Cancer [DOI]
  16. 16 2–47 Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Breast Cancer [DOI]
  17. 17 Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology Patients [DOI]
  18. 18 Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials [DOI]
  19. 19 Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study [DOI]
  20. 20 The New HFA/ICOS Risk Assessment Tool to Identify Patients with Chronic Myeloid Leukaemia at High Risk of Cardiotoxicity [DOI]
  21. 21 Cardiovascular and Cancer Risk: The Role of Cardio-oncology [DOI]
  22. 22 Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment [DOI]
  23. 23 Impact of Baseline Cardiovascular Comorbidity on Outcomes in Women With Breast Cancer: A Real-world, Population-based Study [DOI]
  24. 24 HFA-ICOS cardiovascular toxicity risk score validation in CARDIOTOX registry [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

49

Page views

0

PDF downloads

23

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.